PublicationsMichael Laposata, MD, PhD

1. Laposata, M., S.M. Prescott, T.E. Bross, and P.W. Majerus. 1982. Development and characterization of a tissue culture cell line with essential fatty acid deficiency. Proc. Natl. Acad. Sci. USA 79:7654-7658.
2. Laposata, M., D.K. Dovnarsky, and H.S. Shin. 1983. Thrombin-induced gap formation in confluent endothelial cell monolayers in vitro. Blood 62:549-556.
3. Laposata, M., E.L. Reich, and P.W. Majerus. 1985. Arachidonoyl-CoA synthetase: separation from nonspecific acyl-CoA synthetase and distribution in various cells and tissues. J. Biol. Chem. 260:11016-11020.
4. Majerus, P.W., E.J. Neufeld, and M. Laposata. 1985. Mechanisms for eicosanoid precursor uptake and release by a tissue culture cell line, in Inositol and Phosphoinositides: Metabolism and regulation, Bleasdale, J.E., J. Eichberg, and G. Hauser, eds. 443-457.
5. Brass, L.F., M. Laposata, H. Singh, and S. Rittenhouse. 1986. Regulation of the phosphoinositide hydrolysis pathway in thrombin-stimulated platelets by a pertussis toxin-sensitive guanine nucleotide-binding protein. J. Biol. Chem. 261:16838-16847.
6. Capriotti, A.M. and M. Laposata. 1986. Identification of variables critical to reproducible delipidation of serum. J. Tissue Cult. Methods. 4:219-222.
7. Laposata, M. and P.W. Majerus. 1987. Measurement of icosanoid precursor uptake and release by intact cells. Methods in Enzymology. 141:350-355.
8. Laposata, M., S.L. Kaiser, E.L. Reich, and P.W. Majerus. 1987. Eicosadiynoic acid: A non-toxic inhibitor of multiple enzymatic steps in the production of icosanoids from arachidonic acid. Prostaglandins. 33:603-615.
9. Lowe, J.B., M. Sacchettini, M. Laposata, J.J. McQuillan, and J.I. Gordon. 1987. Expression of rat intestinal fatty acid-binding protein in Escherichia coli. J. Biol. Chem. 262:5931-5937.
10. Brass, L.F. and M. Laposata. 1987. Diacylglycerol causes Ca release from the platelet dense tubular system: comparisons with Ca release caused by inositol 1,4,5-triphosphate. Biochem. Biophys. Res. Commun. 142:7-14.
11. Hicks, D.G., A.M. Connor, and M. Laposata. 1987. Laboratory diagnosis and monitoring of disseminated intravascular coagulation. Lab. Med. 18:585-589. (Reprinted in the Italian journal Biochimica Clinica 13, 30-34, 1989.)
12. Laposata, M., C.M. Krueger, and J.E. Saffitz. 1987. Selective uptake of [3H] arachidonic acid into the dense tubular system of human platelets. Blood. 70:832-837.
13. Laposata, M., S.L. Kaiser, and A.M. Capriotti. 1988. Icosanoid production can be decreased without alterations in cellular arachidonate content or enzyme activities required for arachidonate release and icosanoid synthesis. J. Biol. Chem. 263:3266-3273.
14. Connor, A.M. and M. Laposata. 1988. A rapid assay for thromboxane production by platelets and its use in assessing prior aspirin ingestion. Am. J. Clin. Path. 89:216-221.
15. Capriotti, A.M., E.E. Furth, M.E. Arrasmith and M. Laposata. 1988. Arachidonate released upon agonist stimulation preferentially originates from arachidonate most recently incorporated into nuclear membrane phospholipids. J. Biol. Chem. 263:10029-10034.
16. Furth, E.E. and M. Laposata. 1988. Mass quantitation of agonist induced arachidonate release and icosanoid production in a fibrosarcoma cell line: Effect of time of agonist stimulation, amount of cellular arachidonate, and type of agonist. J. Biol. Chem. 263: 15951-15956.
17. Laposata, M., M. Minda, A.M. Capriotti, E.J. Hartman, and R.V. Iozzo. 1988. Reversible phenotypic modulation induced by deprivation of exogenous essential fatty acids. Lab. Invest. 59:838-847.
18. Tate, G.A., B.F. Mandell, R.A. Karmali, M. Laposata, D.G. Baker, H.R. Schumacher Jr., and R.B. Zurier. 1988. Suppression of monosodium urate crystal induced inflammation by diets enriched with gamma linolenic and eicosapentaenoic acids. Arth. Rheum. 31: 1543-1551.
19. Muszbek, L. and M. Laposata. 1989. Glycoprotein Ib and glycoprotein IX in human platelets are acylated with palmitic acid through thioester linkages. J. Biol. Chem. 264: 9716-9719.
20. Hartman, E.J., S. Omura, and M. Laposata. 1989. Triacsin C: A differential inhibitor of arachidonoyl-CoA synthetase and nonspecific long chain acyl-CoA synthetase. Prostaglandins. 37:655-671.
21. Remaley, A.T., Kennedy, J.M., and M. Laposata. 1989. Evaluation of the clinical utility of platelet aggregation studies. Am. J. Hematol. 31:188-193.
22. Tate, G., B.F. Mandell, M. Laposata, D. Ohliger, D.G. Baker, H.R. Schumacher, and R.B. Zurier. 1989. Suppression of acute and chronic inflammation by enrichment of diet with gamma linolenic acid. J. Rheum. 16:729-733.
23. Muszbek, L. and M. Laposata. 1989. Covalent modification of platelet proteins with palmitate. Blood. 74:1339-1347.
24. Furth, E.E., V. Hurtubise, M.A. Schott, and M. Laposata. 1989. The effect of endogenous essential and non-essential fatty acids on the uptake and subsequent agonist induced release of arachidonate. J. Biol. Chem. 264:18494-18501.
25. Baker, D.G., G. Tate, M. Laposata, and R.B. Zurier. 1989. Suppression of human synovial cell proliferation by dihomo-gamma-linolenic acid. Arth. Rheum. 32:1273-1281.
26. Laposata, M. 1990. Solubilization of arachidonate-CoA ligase from cell membranes, chromatographic separation from nonspecific long-chain fatty acid CoA ligase, and isolation of a mutant cell line defective in arachidonate-CoA ligase. Methods Enzymol. 187:237-242.
27. Pullman-Mooar, S., M. Laposata, D. Lem, and R.B. Zurier. 1990. Alteration of the cellular fatty acid profile and the production of eicosanoids in human monocytes by gamma-linolenic acid. Arth. Rheum. 33:1526-1533.
28. Rubin, D. and M. Laposata. 1991. Regulation of agonist-induced prostaglandin E1 vs. prostaglandin E2 synthesis. A mass analysis. J. Biol. Chem. 266:23618-23623.
29. Rubin, D. and M. Laposata. 1992. Cellular Interactions between n-6 and n-3 Fatty Acids: A mass analysis of fatty acid elongation/desaturation, distribution among complex lipids, and conversion to eicosanoids. J. Lipid Res. 33:1431-1440.
30. Lewandrowski, K., R. Cheek, D. Nathan, K. Hurxthal, and M. Laposata. 1992. Implementation of capillary blood glucose monitoring in a teaching hospital and determination of program requirements to maintain quality testing. Am. J. Med. 93: 419-426.
31. Furth, E.E., H. Sprecher, E. Fisher, H D. Fleishman and M. Laposata. 1992. An in vitro model for essential fatty acid deficiency: Hep G2 cells permanently maintained in lipid-free medium. J. Lipid Res. 33: 1719-1726.
32. McDonagh, J., E.T. Fossel, R.L. Kradin, S.M. Dubinett, M. Laposata, and Y.A. Hallaq. 1992. Effects of TNF-alpha on peroxidation of plasma lipoprotein lipids in experimental animals and patients. Blood. 80:3217-3226.
33. Muszbek, L. and M. Laposata. 1993. Myristoylation of proteins in platelets occurs predominantly through thioester linkages. J. Biol. Chem. 268:8251-8255.
34. Hallaq, Y., T.C. Becker, C.S. Manno, and M. Laposata. 1993. Use of acetyl chloride/methanol for assumed selective methylation of plasma nonesterified fatty acid results in significant methylation of esterified fatty acids. Lipids. 28:355-360.
35. Fujimoto, T., E. Stroud, R.E. Whatley, S.M. Prescott, L. Muszbek, M. Laposata, and R.P. McEver. 1993. P-selectin is acylated with palmitic acid and stearic acid at cysteine 766 through a thioester linkage. J. Biol. Chem. 268:11394-11400.
36. Muszbek, L. and M. Laposata. 1993. Covalent modification of proteins by arachidonate and eicosapentaenoate in platelets. J. Biol. Chem. 268:18243-18248.
37. Doyle, K.M., D. Bird, S. Al-Salihi, Y. Hallaq, J.E. Cluette-Brown, K.A. Goss, and M. Laposata. 1994. Fatty acid ethyl esters are present in human serum following ethanol ingestion. J. Lipid Res. 35: 428-437.
38. Hallak, H., L. Muszbek, M. Laposata, E. Belmonte, L.F. Brass, and D.R. Manning. 1994. Covalent binding of arachidonate to G protein alpha subunits of human platelets. J. Biol. Chem. 269: 4713-4716.
39. Lewandrowski, K., E. M. Bailey, E. Dhanak, M. Laposata, and J. G. Flood. 1994. Mandatory laboratory consultation as a method to aid appropriate test utilization: the case of lactate dehydrogenase isoenzyme analysis. Lab. Med. 25:460-463.
40. Lee-Lewandrowski, E., M. Laposata, K. Eschenbach, C. Camooso, D.M. Nathan, J.E. Godine, K. Hurxthal, J. Goff, and K. B. Lewandrowski. 1994. Utilization and cost analysis of bedside capillary glucose testing in a large teaching hospital: implications for the management of point of care testing. Am. J. Med. 97:222-230.
41. Laposata, M. 1994. The rapidly evolving specialty of laboratory medicine. Laboratory Diagnostics. XXI:65-71.
42. Szczepiorkowski, Z.M., G.R. Dickerson, and M. Laposata. 1995. Fatty acid ethyl esters decrease human hepatoblastoma cell proliferation and protein synthesis. Gastroenterology. 108:515-522. (Selected for review in editorial by A.A. Spector).
43. Teruya, J., J. C. Brown, Z. Szczepiorkowski, and M. Laposata. 1995. Mode of transport of fatty acids to cells influences intracellular fatty acid metabolism. J. Lipid Res. 36:266-276.
44. Laposata M., Z.M. Szczepiorkowski, and J.C. Brown. 1995. Fatty acid ethyl esters: nonoxidative metabolites of ethanol. Prostagl. Leukotr. Ess. FA. 52:87-91.
45. Heith, A.M., C.R. Morse, T. Tsujita, S.
46. Laposata, M. 1995. Fatty Acids: Biochemistry to clinical significance. Am. J. Clin. Path. (Invited review) 104:172-179.
47. Rosetti, R.G., C.M. Seiler, M. Laposata, and R.B. Zurier. 1995. Differential regulation of human and lymphocyte protein kinase C activity by unsaturated fatty acids. Clin. Immunol. Immunopath. 76:220-224.
48. Laposata, M. and K.B. Lewandrowski. 1995. Near patient blood glucose monitoring. Arch. Pathol. Lab. Med. 119:926-928.
49. Bird, D.A., Z.M. Szczepiorkowski, V.C. Trace, and M. Laposata. 1995. Low-density lipoprotein reconstituted with fatty acid ethyl esters as a physiological vehicle for ethyl ester delivery to intact cells. Alcohol Clin. Exp. Res. 19:1265-1269.
50. Al-Eryani, S., A. Kabakibi, J.E. Cluette-Brown, and M. Laposata. 1996. Fatty acid ethyl ester synthase, an enzyme responsible for nonoxidative ethanol metabolism, is present in serum following liver and pancreatic injury. Clin. Chem. 42:24-27.
51. Bernhardt, T.G., P.A. Cannistraro, D.A. Bird, K.M. Doyle, and M. Laposata. 1996. Purification of fatty acid ethyl esters by solid phase extraction and HPLC. J. Chromatog B. 675: 189-196.
52. Laposata, M. and L. Muszbek. 1996. Thioesterification of platelet proteins by saturated and unsaturated fatty acids. Lipids. 31:S-217 - S-221.
53. Gorski, N.P., H. Nouraldin, D.M. Dube, F.I. Preffer, D.M. Dombkowski, E.M. Villa, K.B. Lewandrowski, and M. Laposata. 1996. Reduced fatty acid ethyl ester synthase activity in the white blood cells of alcoholics. Alcohol Clin. Exp. Res. 20: 268-274.
54. Hallaq, Y., J. Teruya, J.E. Cluette-Brown, Z.M. Sczepiorkowski, and M. Laposata. 1996. Stability of plasma nonesterified arachidonate in healthy individuals in fasting and non-fasting states. Clin. Chem. 42: 771-773.
55. Bird, D.A., M. Laposata (corresponding author), and J.A. Hamilton. 1996. Binding of ethyl oleate to low density lipoprotein, phospholipid vesicles, and albumin: A 13C NMR study. J. Lipid Res. 37:1449-1458.
56. Doyle, K.M., J.E. Cluette-Brown, D.M. Dube, T.G. Bernhardt, C.R. Morse, and M. Laposata. 1996. Fatty acid ethyl esters in the blood as markers for ethanol intake. J. Am. Med. Assn. 276: 1152-1156.
57. Zurier, R.B., R.G. Rosetti, E.W. Jacobson, D.M. DeMarco, N.Y. Liu, J.E. Temming, B.M. White, and M. Laposata. 1996. Gamma-linolenic acid treatment of rheumatoid arthritis: a randomized placebo-controlled trial. Arth. Rheum. 39:1808-1817.
58. Laposata, M. 1996. What we are doing or should be doing in Clinical Pathology (special article). Am. J. Clin. Pathol. 106:571-573.
59. Gertler, J.P., R.P. Cambria, D.C. Brewster, J.K. Davison, P. Purcell, S. Zannetti, S. Johnson, G. L'Italien, G. Koustas, G.M. LaMuraglia, M. Laposata, and W.M. Abbott. 1996. Coagulation changes during thoracoabdominal aneurysm repair. J. Vasc. Surg. 24:936-943.
60. Dan, L. and M. Laposata. 1997. Ethyl palmitate and ethyl oleate are the predominant fatty acid ethyl esters in the blood after ethanol ingestion and their synthesis is differentially influenced by the extracellular concentrations of their corresponding fatty acids. Alcohol Clin. Exp. Res. 21:292-296.
61. Bird, D.A. A. Kabakibi, and M. Laposata. 1997. The distribution of fatty acid ethyl esters among lipoproteins and albumin in human serum. Alcohol Clin. Exp. Res. 21: 602-605.
62. Werner, J., M. Laposata (corresponding author), C. Fernandez-del Castillo, M. Saghir, R.V. Iozzo, K.B. Lewandrowski, and A.L. Warshaw. 1997. Pancreatic injury induced by fatty acid ethyl ester, a nonoxidative metabolite of alcohol. Gastroenterology. 113: 286-294. (Selected for review in editorial by J.S. Wilson and R.C. Pirola).
63. Van Cott, E.M., L. Muszbek, and M. Laposata. 1997. Fatty acid acylation of platelet proteins. Prostagl. Leukotr. Ess. FA. 57:33-37.
64. Saghir, M., J. Werner, and M. Laposata. 1997. Rapid in vivo hydrolysis of fatty acid ethyl esters, toxic nonoxidative ethanol metabolites. Am. J. Physiol. 273 (Gastrointest. Liver Physiol. 36):G184-G190.
65. Rossetti, R.G., C.M. Seiler, P. DeLuca, M. Laposata, and R.B. Zurier. 1997. Oral administration of unsaturated fatty acids: Effects on human peripheral blood T lymphocyte proliferation. J. Leukoc. Biol. 62:438-443.
66. Kirby, J.E. and M. Laposata. 1997. The nature and extent of training activities in clinical pathology required for effective consultation on the selection and interpretation of laboratory tests. Arch. Pathol. Lab. Med. 121:1163-1167.
67. Grinspoon, S.K., H. Askari, M.L. Landt, D.M. Nathan, D.A. Schoenfeld, D.L. Hayden, M. Laposata, J. Hubbard, and A.M. Klibanski. 1997. Effects of fasting and refeeding on leptin in humans. Am J. Clin. Nutr. 66:1352-1356.
68. Pascual, M., R. Thadhani, M. Laposata, W.W. Williams, M.L. Farrell, S. M. Johnson, N. Tolkoff-Rubin, and A.B. Cosimi. 1997. Anticardiolipin antibodies and hepatic artery thrombosis after liver transplantation. Transplantation. 64:1361-1364.
69. Muszbek, L., E. Racz, and M. Laposata. 1997. Posttranslational modification of proteins with fatty acids in platelets. Prostagl. Leukotr. Ess. FA. 57:359-366.
70. Laposata, M. 1998. Fatty acid ethyl esters: ethanol metabolites which mediate ethanol – induced organ damage and serve as markers of ethanol intake. Prog. Lipid Res. 37: 307-316.
71. Laposata, M. 1998. Fatty acid ethyl esters: nonoxidative metabolites of ethanol (invited review). Addiction Biology. 3:5-14.
72. Kabakibi, A., E.C. Vamvakas, P.A. Cannistraro, Z. M. Szczepiorkowski, and M. Laposata. 1998. Collagen-induced whole blood platelet aggregation in patients undergoing surgical procedures associated with minimal to moderate blood loss. Am. J. Clin. Path. 109:392-398.
73. Kabakibi, A., C.R. Morse, and M. Laposata. 1998. Fatty acid ethyl esters and Hep2 cells: intracellular synthesis and release from the cells. J. Lipid Res. 39:1568-1582.
74. Dan, L. and M. Laposata. 1998. Quantitation of the mass fatty acid ethyl esters synthesized by HepG2 cells incubated with ethanol. Alcohol Clin. Exp. Res. 22:1125-1131.
75. Laposata, M., D. Green, E.M. Van Cott, T.W. Barrowcliffe, S.M. Goodnight, and R.C. Sosolik. 1998. The clinical use and laboratory monitoring of low molecular weight heparin, danaparoid, hirudin and related compounds, and argatroban. Arch. Path. Lab. Med. 122:799-807.
76. Van Cott, E.M. and M. Laposata. 1998. Laboratory evaluation for hypercoagulable states. Hematol. Oncol. Clin. NA, 12:1141-1166.
77. Cunningham, M.T., J. Praestegaard, P.E. Stryer, J.T. Brandt, R.B. Fairweather, M. Laposata, J.D. Olson, R.C. Sosolik, and D.A. Triplett. 1999. A method for proficiency testing of small peer groups in the College of American Pathologists Coagulation Surveys. Arch. Pathol. Lab. Med.123:199-205.
78. Goss, K.A., R. Alharethi, and M. Laposata. 1999. Fatty acid ethyl ester synthesis in the preparation of scotch whiskey. Alcohol.17:241-245.
79. Quinn, D.A., R.B. Fogel, C.D. Smith, M. Laposata, B.T. Thompson, S.M. Johnson, A.C. Waltman, and C.A. Hales. 1999. D-dimers in the diagnosis of pulmonary embolism. Am. J. Resp. Crit. Care Med. 159:1445-1449.
80. Muszbek, L., G. Haramura, J.E. Cluette-Brown, E.M. Van Cott, and M. Laposata. 1999. The pool of fatty acids covalently bound to platelet proteins by thioester linkages can be altered by exogenously supplied fatty acids. Lipids 34:S331-S337.
81. Laposata, M. 1999. Fatty acid ethyl esters: Nonoxidative ethanol metabolites with emerging biological and clinical significance. Lipids 34:S281-S285.
82. Laposata, M. Fatty acid ethyl esters: Facts and speculations. 1999. Prostagl. Leukotr. Essential Fatty Acids. 60:313-315.
83. Zurier, R.B., R.G. Rosetti, C.S. Seiler, and M. Laposata. 1999. Human peripheral blood T lymphocyte proliferation after activation of the T cell receptor: Effects of unsaturated fatty acids. Prostagl. Leukotr. Essential Fatty Acids. 60:371-375.
84. Van Cott, E.M. and M. Laposata. 1999. Desirudin. Curr. Op. Cardiovasc. Pulm. Renal Invest. 1:159-170.
85. Laposata, M. 1999. Assessment of ethanol intake: Current assays and new markers on the horizon. Am. J. Clin. Path. 112:443-450.
86. Saghir, M., E. Blodget, and M. Laposata. 1999. The hydrolysis of fatty acid ethyl esters in low density lipoproteins by red blood cells, white blood cells, and platelets. Alcohol. 19:163-168.
87. Freedman, S.D., M.H. Katz, E.M. Parker, M. Laposata, M.Y. Urman, and J.G. Alvarez. 1999. A membrane lipid imbalance plays a role in the phenotypic expression of cystic fibrosis in cftr-/-mice. Proc. Natl. Acad. Sci. U.S.A. 96:13995-14000.
88. Soderberg, B.L., E.T. Sicinska, E. Blodget, J.E. Cluette-Brown, P.M. Suter, T. Schuppisser, W. Vetter, and M. Laposata. 1999. Preanalytical variables affecting the quantitation of fatty acid ethyl esters in plasma and serum samples. Clin. Chem. 45: 2183-2190.
89. Saghir, M., J. Werner, and M. Laposata. 1999. A comparison of the hydrolysis and metabolism in rats of fatty acid ethyl esters within human low density lipoproteins and rat low density lipoproteins. Res. Commun. Alcohol Subst. Abuse. 20:123-134.
90. Laposata, M., A. Kabakibi, M.P. Walden, J.E. Cluette-Brown, Azra A. Nanji, M.A. Refaai, J. Werner, and Amin A. Nanji. 2000. Differences in the fatty acid composition of fatty acid ethyl esters in organs and their secretions. Alcohol. Clin. Exp. Res. 24:1488-1491.
91. Salem, R.O., J.E. Cluette-Brown, A. Hasaba, and M. Laposata. 2001. The effect of specimen anticoagulant and storage on serum and plasma fatty acid ethyl ester concentration measurements. Clin. Chem. 47:126-127.
92. Salem, R.O., M.A. Refaai, J.E. Cluette-Brown, J.W. Russo, and M. Laposata. 2001. Fatty acid ethyl esters in liver and adipose tissues as postmortem markers for ethanol intake. Clin. Chem. 47:722-725.
93. Hasaba, A. and M. Laposata. 2001. The synthesis and secretion of fatty acid ethyl esters from Hep G2 cells are stimulated by lipoproteins and albumin. Alcohol. Clin. Exp. Res. 25:338-343.
94. Kang, Z.B., Y. Ge, Z. Chen, J.E. Cluette-Brown, M. Laposata, A. Leaf, and J.X. Kang. 2001. Adenoviral gene transfer of Caenorhabditis elegans n-3 fatty acid desaturase optimizes fatty acid composition in mammalian cells. Proc. Natl. Acad. Sci., 98:4050-4054.
95. Zybko, W.C., J.E. Cluette-Brown, and M. Laposata. 2001. Improved sensitivity and reduced sample size in serum fatty acid ethyl ester analysis. Clin. Chem. 47:1120-1121.
96. Werner, J., M. Saghir, C. Fernandez-del Castillo, A.L. Warshaw, and M. Laposata. 2001. Linkage of oxidative and non-oxidative ethanol metabolism in the pancreas and toxicity of non-oxidative ethanol metabolites for pancreatic acinar cells. Surgery 129:736-744.
97. Dighe, A.S. and M. Laposata. 2001. Narrative interpretations for clinical laboratory evaluations: An overview. Am. J. Clin. Pathol. (Suppl.). 116:S123-S128.
98. MacMillan, D.H., B.L. Soderberg, and M. Laposata. 2001. Regulations regarding reflexive testing and narrative interpretations in laboratory medicine. Am. J. Clin. Pathol. (Suppl.). 116:S129-S132.
99. Kratz, A., B.L. Soderberg, Z.M. Szczepiorkowski, A.S. Dighe, J. Versalovic, and M. Laposata. 2001. The generation of narrative interpretation in laboratory medicine: A description of individual sign-out rounds. Am. J. Clin. Pathol. (Suppl.). 116:S133-S140.
100. Refaai, M.A., P.N. Nguyen, T.S. Steffensen, R.J. Evans, J.E. Cluette-Brown, and M. Laposata. 2002. Liver and adipose fatty acid ethyl esters obtained at autopsy are postmortem markers for premortem ethanol intake. Clin. Chem. 48:77-83.
101. Meininger, G., H. Hadigan, M. Laposata, J. Brown, J. Rabe, J. Louca, N. Aliabadi, and S.M. Grinspoon. 2002. Elevated concentrations of free fatty acids are associated with increased insulin response to standard glucose challenge in human immunodeficiency virus-infected subjects with fat redistribution. Metabolism. 51:260-266.
102. Cunningham, M.T., J.T. Brandt, M. Laposata, and J.D. Olson. 2002. Laboratory diagnosis of dysfibrinogenemia. Arch. Pathol. Lab. Med. 126:499-505.
103. Van Cott, E.M., B.L. Soderberg, and M. Laposata. 2002. Activated protein C resistance, the factor V Leiden mutation, and a laboratory testing algorithm. Arch. Pathol. Lab. Med. 126:577-582.
104. Kratz, A. and M. Laposata. 2002. Enhanced clinical consulting – moving toward the core competencies of laboratory professionals. Clin. Chim. Acta. 319:117-125.
105. Van Cott, E.M. B.L. Soderberg, and M. Laposata. 2002. Hypercoagulability test strategies in the protein C and protein S pathway. Clin. Lab. Med. 22:391-403.
106. Ge, Y., Z. Chen, Z.B. Kang, J. Cluette-Brown, M. Laposata, and J.X. Kang. 2002. Effects of adenoviral gene transfer of C. elegans n-3 fatty acid desaturase on the lipid profile and growth of human breast cancer cells. Anticancer Res. 22:537-543.
107. Nanji, A.A., G.L. Su, M. Laposata, and S.W. French. 2002. Pathogenesis of alcoholic liver disease – recent advances. Alcohol. Clin. Exp. Res. 26:731-736.
108. Werner, J., M. Saghir, A.L. Warshaw, K.B. Lewandrowski, M. Laposata, R.V. Iozzo, E.A. Carter, R.J. Schatz, and C. Fernandez-del Castillo. 2002. Alcoholic pancreatitis in rats: injury from nonoxidative metabolites of ethanol. Am. J. Physiol. 283:G65-73.
109. Laposata, M., A. Hasaba, C.A. Best, D.M. Yoerger, B.M. McQuillan, R.O. Salem, M.A. Refaai, and B.L. Soderberg. 2002. Fatty acid ethyl esters: Recent observations. Prostagl. Leukotr. Essential Fatty Acids. 67:193-196.
110. Brenner, B.R., U. Nowak-Gottl, A. Kosch, M. Manco-Johnson, and M. Laposata. 2002. Diagnostic studies for thrombophilia in women on hormonal therapy and during pregnancy, and in children. Arch. Pathol. Lab. Med. 126:1296-1303.
111. Van Cott, E.M., M. Laposata, and M.H. Prins. 2002. Laboratory evaluation of hypercoagulability with venous or arterial thrombosis: venous thromboembolism, myocardial infarction, stroke and other conditions. Arch. Pathol. Lab. Med. 126:1281-1295.
112. Refaai, M.A., M. Laposata, and E.M. Van Cott. 2003. Clinical significance of a borderline titer in a negative ELISA test for heparin-induced thrombocytopenia. Am. J. Clin. Path. 119:61-65.
113. Best, C.A., J.E. Cluette-Brown, M. Teruya, A. Teruya and M. Laposata. 2003. Red blood cell fatty acid ethyl esters: A significant component of fatty acid ethyl esters in the blood. J. Lipid Res. 44:612-620.
114. Best, C.A. and M. Laposata. 2003. Fatty acid ethyl esters: Toxic non-oxidative markers of ethanol and markers of ethanol intake. Front. Biosci. 8, E202-E217.
115. Refaai, M., E.M. Van Cott, and M. Laposata. 2003. The timing of a positive test for heparin induced thrombocytopenia relative to the platelet count and anticoagulant therapy in 43 consecutive cases. Am. J. Clin. Path. 119:497-504.
116. Hartnett, M.E., M. Laposata, and E.M. Van Cott. 2003. Antiphospholipid antibody syndrome in a six-year-old female patient. Am. J. Ophthalmol. 135:542-544.
117. Refaai, M., P.N. Nguygen, J.E. Cluette-Brown, and M. Laposata. 2003. Ethyl arachidonate is the predominant fatty acid ethyl ester in the brain of subjects with detectable blood ethanol at the time of death. Lipids. 38:269-273.
118. Laposata, M. and S. M. Johnson. 2003. Assessment of the stability of dalteparin sodium in prepared syringes for up to 30 days: An in vitro study. Clin. Therap. 25:1219-1225.
119. Soderberg, B.L., R.O. Salem, C.A. Best, J.E. Cluette-Brown, and M. Laposata. 2003. Fatty acid ethyl esters: Ethanol metabolites that reflect ethanol intake. Am. J. Clin. Path. (Suppl.) 119: S94-99.
120. Hasaba, A. J.E. Cluette-Brown, and M. Laposata. 2003. Stearic acid stimulates fatty acid ethyl ester synthesis in HepG2 cells exposed to ethanol. Lipids. 38:1051-1055.
121. Freedman, S.D., P.G. Blanco, M.M. Zaman, J.C. Shea, M. Ollero, I.K. Hopper, D.A. Weed, A. Gelrud, M.M. Regan, M. Laposata, J.G. Alvarez, and B.P. O’Sullivan. 2004. Association of cystic fibrosis with abnormalities in fatty acid metabolism. N. Engl. J. Med. 350:560-569.
122. Van Cott, E.M., M. Laposata, and M.E. Hartnett. 2004. Prothrombin gene mutation G20210A, homocysteine, antiphospholipid antibodies, and other hypercoagulable states in ocular thrombosis. Blood Coag. Fibrinol. 15:393-397.
123. Blanco, P.G., S.D. Freedman, M.C. Lopez, M. Ollero, E. Comen, M. Laposata, J.G. Alvarez. 2004. Oral docosahexaenoic acid given to pregnant mice increases the amount of surfactant in lung and amniotic fluid in preterm fetuses. Am. J. Obstet. Gynecol. 190:1369-1374.
124. Laposata, M.E., M. Laposata (corresponding author), E.M. Van Cott, D.S. Buchner, M.S. Kashalo, and A.S. Dighe. 2004. Physician survey of a laboratory medicine interpretative service and evaluation of the influence of interpretations on laboratory test ordering. Arch. Pathol. Lab. Med. 128:1424-1427.
125. O’Sullivan, B.P., M.D. Linden, A.L. Frelinger III, M.R. Barnard, M. Spencer-Manzon, J.E. Morris, R.O. Salem, M. Laposata, and A.D. Michelson. 2005. Platelet activation in cystic fibrosis. Blood. 105:4635-4641.
126. Salem, R.O. and M. Laposata. 2005. Effects of alcohol on hemostasis. Am. J. Clin. Path. Suppl. 123:S96-105.
127. Laposata, M.E. and M. Laposata. 2005. Children presenting with symptoms of child abuse: When is it not abuse? Am. J. Clin. Path. Suppl. 123:S119-124.
128. Knoepp, S.M. and M. Laposata. 2005. Aspirin resistance: Moving forward with multiple definitions, different assays, and a clinical imperative. Am. J. Clin. Path. Suppl. 123:S125-132.
129. Bisaga, A., M. Laposata, S. Xie, and S.M. Evans. 2005. Comparison of serum fatty acid ethyl esters and urinary 5-hydroxytryptophol as biochemical markers of recent ethanol consumption. Alcohol. 40:214-218.
130. Aleryani, S., J.E. Cluette-Brown, Z.A. Khan, H. Hasaba, L. Lopez de Heredia, and M. Laposata. 2005. Fatty acid methyl esters are detectable in the plasma and their presence correlates with liver dysfunction. Clin. Chim. Acta. 359:141-149.
131. Canavan B, Salem RO, Schurgin S, Koutkia P, Lipinska I, Laposata M, Grinspoon S. 2005. Effects of physiologic leptin administration on markers of inflammation, platelet activation and platelet aggregation during caloric deprivation. J. Clin. Endocrinol. Metab. 90:5779-5785.
132. Blanco, P.G., R.O. Salem, M. Ollero, M.M. Zaman, J.E. Cluette-Brown, S.D. Freedman, and M. Laposata. 2005. Ethanol administration to cystic fibrosis knockout mice results in increased fatty acid ethyl ester production. Alcohol Clin. Exp. Res. 29:2039-2045.
133. Salem, R.O., J.E. Cluette-Brown, M. Laposata. 2005. Fatty acid ethyl ester, nonoxidative ethanol metabolite: synthesis, uptake, and hydrolysis by human platelets. Biochim. Biophys. Acta. 1738:99-104.
134. Salem, R.O., and M. Laposata. 2006. Fatty Acid Ethyl Ester, a Nonoxidative Ethanol Metabolite, Reverses the Inhibitory Effect of Ibuprofen on Platelet Aggregation. J. Thromb. Haemost. 4:275-276.
135. Alhomsi, K., J.E. Cluette-Brown, M. Laposata. 2006. Fatty acid ethyl esters in human mononuclear cells: production by endogenous synthesis greatly exceeds the uptake of preformed ethyl esters. Alcohol. Clin. Exp. Res. 30:560-566.
136. Yoerger D.M., C.A. Best, B.M. McQuillan, G.E. Supple, J.L. Guererro, J.E. Cluette-Brown, A. Hasaba, M.H. Picard, J.R. Stone, M. Laposata. 2006. Rapid fatty acid ethyl ester synthesis by porcine myocardium upon ethanol infusion into the left anterior descending coronary artery. Am. J. Pathol. 168:1435-1442.
137. Alhomsi, K. and M. Laposata. 2006. Fatty acid ethyl ester effects on interleukin-2 production, cyclic AMP synthesis, and calcium influx in human mononuclear cells. Alcohol Clin. Exp. Res. 30:1121-1125.
138. Best, C.A., T. Sarkola, C.J.P. Eriksson, J.E. Cluette-Brown, M. Laposata. 2006. Increased plasma fatty acid ethyl ester levels following inhibition of oxidative metabolism of ethanol by 4-methylpyrazole treatment in human subjects. Alcohol. Clin. Exp. Res. 30: 1126-1131.
139. Pysher, T.J., P.R. Bach, S.M. Geaghan, M.S. Hamilton, M. Laposata, G. Lockitch, C. Brugnara, C.M. Coffin, M. Pasquali, P. Rinaldo, W.L. Roberts, J.C. Rutledge, E.R. Ashwood, R.C. Blaylock, J. Campos, B. Goldsmith, P.M. Jones, M. Lim, A.W. Meikle, S.L. Perkins, D.A. Perry, C.A. Petti, B.B. Rogers, P. Steele, R.L. Weiss, and G. Woods. 2006. Teaching pediatric laboratory medicine to pathology residents. Arch. Pathol. Lab. Med. 130:1031-1038.
140. Alsfasser, G., A.L. Warshaw, S.P. Thayer, B. Antoniu, M. Laposata, K.B. Lewandrowski, C. Fernandez-del Castillo. 2006. Decreased inflammation and improved survival with recombinant human activated protein C treatment in experimental acute pancreatitis. Arch. Surg. 141: 670-676.
141. Best, C.A., M. Laposata, V.G. Proios, Z.M. Szczepiorkowski. 2006. Method to assess fatty acid ethyl ester binding to albumin. Alcohol. 41:240-246.
142. Yeh R.W., B.M. Everett, S.Y. Foo, D.J. Dorer, M. Laposata, E.M. Van Cott, I.K. Jang. 2006. Predictors for the development of elevated anti-heparin/platelet factor IV antibody titers in patients undergoing cardiac catheterization. Am. J. Cardiol. 98:419-421.
143. Foo, S.Y., B.M. Everett, R.W. Yeh, D. Criss, M. Laposata, E.M. Van Cott, I.K. Jang. 2006. Prevalence of heparin-induced thrombocytopenia in patients undergoing cardiac catheterization. Am. Heart J. 152:290. e1-7.
144. Ollero, M., M. Laposata, M.M. Zaman, P.G. Blanco, C. Andersson, J. Zeind, Y. Urman, G. Kent, P. Durie, J.G. Alvarez, S.D. Freedman. 2006. Evidence of increased flux to n-6 docosapentaenoic acid in phospholipids of pancreas from cftr -/- knockout mice. Metabolism 55:1192-1200.
145. Melanson S.E.F., M. Laposata, C.A. Camargo, Jr., A.A. Chen, R. Tung, D. Krauser, S. Anwaruddin, A. Baggish, R. Cameron, P. Sluss, K.B. Lewandrowski, E. Lee-Lewandrowski, J.L. Januzzi. 2006. Combination of D-Dimer and Amino-Terminal Pro-B-Type Natriuretic Peptide Testing for the Evaluation of Dyspneic Patients with and without Acute Pulmonary Embolism. Arch. Pathol. Lab. Med. 130:1326-1329.
146. Salem, R.O. and M. Laposata. 2006. Activation and impairment of platelet function in vitro by fatty acid ethyl ester, a nonoxidative ethanol metabolite. Alcohol. Clin. Exp. Res. 30: 2079-2088.
147. Popescu, P., T. Ikeda, K. Goda, C.A. Best, M. Laposata, S. Manley, R. R. Dasari, K. Badizadegan, M.S. Feld. 2006. Optical measurement of cell membrane tension. Phys. Rev. Lett. 97:218101.
148. Batel, I., M.-B. Ericsoussi, J.E. Cluette-Brown, B.P. O’Sullivan, S.D. Freedman, J.E. Savaille, M. Laposata. 2007. Potential utility of plasma fatty acid analysis in the diagnosis of cystic fibrosis. Clin. Chem. 53:78-84.
149. Everett, B.M., R. Yeh, S.Y. Foo, D. Criss, E.M. Van Cott, M. Laposata, W.D. Hoffman, E. Avery, J. Walker, D. Torchiana, I.K. Jang. 2007. Prevalence of heparin/platelet factor 4 antibodies before and after cardiac surgery. Ann. Thor. Surg. 83:592-597.
150. Wozniak, J., J. Biederman, E. Mick, J. Waxmonsky, L. Hantsoo, C.A. Best, J.E. Cluette-Brown, and M. Laposata. 2007. Omega-3 fatty acid monotherapy for pediatric bipolar disorder. A prospective open label trial. Eur. Neuropsychopharm. 2007, 17:440-447.
151. Salem, R.O., M. Laposata, R. Rajendram, J.E. Cluette-Brown, V.R. Preedy. 2007. The total body mass of fatty acid ethyl esters in skeletal muscles following ethanol exposure greatly exceeds that found in the liver and the heart. Alcohol Alcohol. 41:598-603.
152. Laposata, M. and A.S. Dighe. 2007. “Pre-pre” and “post-post” analytical error: High incidence patient safety hazards involving the clinical laboratory. Clin. Chem. Lab. Med. 45:712-719.
153. Peershke, E.I., Y. Agrawal, C-B. Alexander, E. Bovill, and M. Laposata. 2007. Proposed research training guidelines for residents in laboratory medicine. Clin. Lab Med. 27:241-253.
154. Al-Turkmani, R., S.D. Freedman, and M. Laposata. 2007. Fatty acid alterations and n-3 fatty acid supplementation in cystic fibrosis. Prostaglandins, Leukotrienes, Ess. Fatty Acids. 77:309-318.
155. Alhomsi, K., M. Selig, T. Sustic, E. Katrangi, V. Weissig, and M. Laposata. 2008. Induction of apoptosis and necrosis in human peripheral blood mononuclear cells by fatty acid ethyl esters. Alcohol. Clin. Exp. Res. 32:534-543.
156. Mischoulon, D., C. Best-Popescu, M .Laposata, W. Merens, J.L. Murakami, S. Wu, G.I. Papakostas, C.M. Dording, S.B. Sonawalla, A.A. Nirenberg, J.E. Alpert, and M. Fava. 2008. A double-blind dose, finding pilot study of docosahexaenoic acid (DHA) for major depressive disorder. 2008. Eur. Neuropsychopharm. 18:639-645.
157. Anderson, C., M.R. Al-Turkmani, J.E. Savaille, R. Alturkmani, W. Katrangi, J.E. Cluette-Brown, M.M. Xaman, M. Laposata, and S.D. Freedman. 2008. Cell culture models demonstrate that CFTR dysfunction leads to defective fatty acid and composition metabolism. J. Lipid Res. 49:1692-1700.
158. Al-Turkmani, M.R., C. Anderson, R. Alturkmani, W. Katrangi, J.E. Cluette-Brown, S.D. Freedman and M. Laposata. 2008. A mechanism accounting for the low cellular level of linoleic acid in cystic fibrosis and its reversal by DHA. J. Lipid Res. 49:1946-1954.
159. Avery, E.G., A.D. Hilgenberg, R.P. Cambria, R. Beckerly and M. Laposata. 2009. Successful use of bivalirudin for combined carotid endarterectomy and coronary revascularization with the use of cardiopulmonary bypass in a patient with an elevated heparin-platelet factor 4 antibody titer. Anes. Analges. 108:1113-1115.
160. Piva, E., L. Sciacovelli, M. Zaninotto, M. Laposata, and M. Plebani. 2009. Evaluating laboratory critical value reporting and improving communication. Am. J. Clin. Path. 131:432-441.
161. Piva, E., L. Sciacovelli, M. Zaninotto, M. Laposata, and M. Plebani. 2009. Evaluation of effectiveness of a computerized notification system for reporting critical values. Am. J. Clin. Pathol. 131:432-441.
162. Piva, E., L. Sciacovelli, M. Laposata, and Plebani, M. 2010. Assessment of critical values policies in Italian institutions: Comparison with the US situation. Clin. Chem. Lab. Med. 48:461-468.
163. Zaman, M.M., C.R. Martin, C. Andersson, A.Q. Bhutta, J.E. Cluette-Brown, M. Laposata, and S.D. Freedman. 2010. Linoleic acid supplementation results in increased arachidonic acid and eicosanoid production in CF airway cells and in cftr-/-transgenic mice. Am. J. Physiol. Lung Cell Mol. Physiol. 299:L599-L606.
164. Njoroge, S.W., A.C. Seegmiller, and M. Laposata. 2011. Increased ∆5-and ∆6-desaturase cyclooxygenase-2, and lipoxygenase-5 expression are associated with fatty acid and eicosanoid changes in cystic fibrosis. Biochem. Biophys. Acta – Molec. Cell Biol. Lipids. 1811:431-440.
165. Thomsen, K.F., M. Laposata, S.W. Njoroge, O.C. Umunakwe, W. Katrangi, and A.C. Seegmiller. 2011. Increased elongase and ∆9-desaturase activity are associated with n-7 and n-9 unsaturated fatty acid abnormalities in cystic fibrosis. Lipids. 46:669-677.
166. Plebani, M., M. Laposata, and G.D. Lundberg. 2011. The brain-to-brain loop concept 40 years after its introduction. Am. J. Clin. Path. 136:829-833.
167. Gehrie, E. and M. Laposata. 2011. Test of the Month: The chromogenic antifactor Xa assay. Am. J. Hematol. 87:194-196.
168. LaMuraglia, G.M., R. Houbballah, and M. Laposata. 2012. The identification and management of heparin-induced thrombocytopenia in the vascular patient. J. Vasc. Surg. 55:562-570.
169. Pulley, J.M., J.C. Denny, J.F. Peterson, G.R. Bernard, C.L. Vnencak-Jones, A.H. Ramirez, J.T. Delaney, E. Bowton, K. Brothers, K. Johnson, D.C. Crawford, J. Schildcrout, D.R. Masys, H.H. Dilks, R.A. Wilke, E.W. Clayton, E. Shultz, M. Laposata, J. McPherson, J.N. Jirjis, D.M. Roden. 2012. Operational Implementation of Prospective Genotyping for Personalized Medicine: The design of the Vanderbilt PREDICT Project. Clin. Pharmacol. Ther. 92:87-95.
170. Njoroge, S.W., M. Laposata, W. Katrangi, and A.C. Seegmiller. 2012. DHA and EPA reverse cystic fibrosis-related fatty acid abnormalities by suppressing fatty acid desaturase expression and activity. J. Lipid Res. 53:257-265.
171. Tcherniantchouk, O., M. Laposata, and M.B. Marques. 2013. The isolated prolonged PTT. Am J Hematol. 88:82-85.
172. Katrangi, W., J. Lawrenz, A. C. Seegmiller, and M. Laposata. 2013. Interactions of linolenic and alpha-linolenic acids in the development of fatty acid alterations in cystic fibrosis. Lipids. 48:333-342.
173. Sephel, G.C. and M. Laposata. 2013. Transiently increased variation between a point-of-care laboratory INR method after a long period of correlation: A case study demonstrating the need for ongoing correlation of POC with the central laboratory. Am. J. Clin. Path. 140:475-486.
174. Cole, B., J.A. Dickerson, M.L. Graber, C.R. Fantz, M. Laposata, K. Henricksen, M.L. Astion, and P. Epner. 2014. A prospective tool for risk assessment of sendout testing. Am. J. Clin. Path. 434:1-5.
175. Laposata, M. 2014. Putting the patient first – using the expertise of laboratory professionals to produce rapid and accurate diagnoses. Lab. Med. 45:4-5.
176. Njoroge, S.W., M. Laposata, K.L. Boyd, and A.C. Seegmiller. 2015. Polyunsaturated fatty acid supplementation reverses cystic fibrosis-related fatty acid abnormalities in CFTR (-/-) mice by suppressing fatty acid desaturases. J. Nutr. Biochem. 26:36-43.
177. O’Connor, M.G., K. Thomsen, R.F. Brown, M. Laposata, and A. Seegmiller. 2016. Elevated prostaglandin E metabolites and abnormal plasma fatty acids at baseline in pediatric cystic fibrosis patients: A pilot study. Prostaglandins Leukot Essent Fatty Acids 113:46-49.
178. Peterson, J.F., J.R. Field, K.M. Unertl, J.S. Schildcrout, D.C. Johnson, Y. Shi, I. Danciu, J.H. Cleator, J.M. Pulley, J.A. McPherson, J.C. Denny, M. Laposata, D.M. Roden, and K.B. Johnson. 2016. Physician response to implementation of genotype-tailored antiplatelet therapy. Clin. Pharmacol. Ther. 100:67-74.
179. Peterson, J.F., J.R. Field, Y. Shi, J.S. Schildcrout, J.C. Denny, T. L. McGregor, S.L. Van Driest, J.M. Pulley, I.M. Lubin, M. Laposata, D.M. Roden, and E.W. Clayton. 2016. Attitudes of clinicians following large-scale pharmacogenomics implementation. Pharmacogenomics J.16:393-398.
180. Belk, K.W., M. Laposata, and C. Craver. 2016. A comparison of red blood cell transfusion utilization between anti-activated factor X and activated partial thromboplastin monitoring in patients receiving unfractionated heparin. J. Thromb. Haemost. 14:1-10.
181. Sarkar, M.K., C. Botz, and M. Laposata. 2017. An assessment of overutilization and underutilization of laboratory tests by expert physicians in the evaluation of patients for bleeding and thrombotic disorders in clinical context and in real-time. Diagnosis 4:21-26.
182. Graber, M.L., D. Rusz, M.L. Jones, D. Farm-Franks, B. Jones, J. Cyr Gluck, D.B. Thomas, K. Gleason, K. Welte, J. Abfalter, K. Westerhaus, G. Adams, M. Laposata, Q. Eichbaum, T. Nabatchi, and M. Compton. 2017. The new diagnostic team. Diagnosis 4:225-238.
183. Laposata, M. 2018. Obtaining a correct diagnosis rapidly in the United States is associated with many barriers not present in other countries. Am. J. Clin. Pathol. 149:458-460.
184. Baird, G.S., B.R. Jackson, J. Dickerson, K. Sikaris, B. Croal, and M. Laposata, 2018. What’s new in laboratory test utilization management? Clin. Chem. 64:994-1000.
185. Laposata, M. 2018. The definition and scope of diagnostic error in the US and how diagnostic error is enabled. J. Appl. Lab. Med. 3:128-134.
186. Verna, R., A.B. Velazquez, and M. Laposata, 2019. Reducing diagnostic errors worldwide through diagnostic management teams. Ann. Lab. Med. 39:121-124.
187. Sarkar, M.K. and M. Laposata. 2019. Is aspirin best choice today for prophylaxis against venous thromboembolism after orthopedic surgery? TX Orthop. J. 4:?.
188. Plebani, M., M. Laposata, and G. Lippis. 2019. Driving the route of laboratory medicine: A manifesto for the future. Intern Emerg Med 14:337-340.
189. Plebani, M., M. Laposata, and G. Lippi. 2019. A Manifesto for the Future of Laboratory Medicine Profssionals. Clin Chem Acta 489:49-52.
190. Ducatman, B.S., Ducatman, A.M., Crawford, J.M., Laposata, M., and Sanfilippo F. 2020. The value proposition for pathologists: A population health approach. Acad Pathol doi/10.1177/2374289519898857.

1. Laposata, M., A.M. Connor, D.G. Hicks, and D.K. Phillips. 1989. The Clinical Hemostasis Handbook. Yearbook/Mosby Medical Publishers. Chicago, IL.
2. Laposata, M. 1992. The New England Journal of Medicine SI Unit Conversion Guide. NEJM Books. Boston, MA.
3. Laposata, M. Editor, 2002. Laboratory Medicine: Clinical Pathology in the Practice of Medicine. ASCP Press. Chicago, IL.
4. Laposata, M. Editor, 2010. Laboratory Medicine: The Diagnosis of Disease in the Clinical Laboratory, First Edition. (Lange series textbook). McGraw-Hill. New York. Author or co-author of 7 chapters in this textbook. (With translations into Italian and Chinese)
5. Laposata, M. 2010-2013. Coagulation Disorders: Quality in Laboratory Diagnosis and editor for entire series of 6 textbooks for Quality in Laboratory Diagnosis (Laboratory Management, Clinical Microbiology, Transfusion Medicine, Clinical Chemistry, and Hematology/Clinical Immunology). Demos Medical Publishers. New York.
6. Laposata, M., editor with S.E. Melanson, and D.S. Alter, Associate Eds. 2013. Laboratory Medicine. Publisher – Decision Support in Medicine (Electronic Program).
7. Laposata, M. Editor, 2014. Laboratory Medicine: The Diagnosis of Disease in the Clinical Laboratory. Second Edition. (Lange series textbook). McGraw-Hill. New York. Author or co-author of 7 chapters in this textbook.
8. Laposata, M. Clinical Diagnostic Tests: How to Avoid Errors in Order Tests and Interpreting Results. 2016. Demos Medical Publishers. New York.
9. Laposata, M. Editor, 2019. Laposata’s Laboratory Medicine: The Diagnosis of Disease in the Clinical Laboratory. Third Edition. (Lange Series textbook). McGraw-Hill. China.

1. Zurier, R.B., D.G. Baker, D. DeMarco, J.C. Fantone, M. Laposata, D. Santoli, and G. Tate. 1990. Anti-inflammatory Effects of Gamma Linolenic Acid: Studies in Animals and Cultured Cells. In Omega-6 Essential Fatty Acids: Pathophysiology and Roles in Clinical Medicine pp 203-221. Alan R. Liss Publishers, New York.
2. Yang, J., M. Laposata, and K.B. Lewandrowski. 1996. Algorithmic Diagnosis. In Handbook of Clinical Automation, Robotics and Optimization. G. J. Kost, ed. John Wiley & Sons, Inc. Publishers, New York. pp. 911-928.
3. Van Cott, E.M. and M. Laposata. 2001. Coagulation, Fibrinolysis and hypercoagulation. In: Henry, J.B., ed. Clinical Diagnosis and Management by Laboratory Methods, 20th ed. WB Saunders Company, New York. pp. 642-659.
4. Szczepiorkowski, Z.M. and M. Laposata. 2001. Fatty Acid Ethyl Esters: Toxic Nonoxidative Metabolites of Ethanol. In Mostofsky, D. et al. eds. Fatty Acids: Physiological and Behavioral Functions, Humana Press, Totowa, NJ.
5. Van Cott, E.M. and M. Laposata. 2001. Coagulation. In Jacobs DS et al, ed. The Laboratory Test Handbook, 5th ed. Lexi-Comp, Cleveland. pp. 327-358.
6. Abel, G.A. and M. Laposata. Lipids and Lipoproteins. 2002. In McClatchey, K.A., ed. Clinical Laboratory Medicine, 2nd ed. Lippincott, Williams and Wilkins, Baltimore. pp. 306-321.
7. Abel, G.A. and M. Laposata. 2002. Lipids, Lipoproteins, and Cardiovascular Risk Assessment. In Lewandrowski, K.B. ed. Clinical Chemistry: Laboratory Management, Analytical Principles, and Clinical Correlations. Lippincott, Williams and Wilkins, Baltimore. pp. 575-591.
8. Refaai, M.A. and M. Laposata. Platelet Count. 2002. In Michaelson, A.E., ed. Platelets. Academic Press, Boston. pp. 279-282.
9. Refaai, M.A. and M. Laposata. 2002. Platelet Aggregation. In Michaelson, A.E., ed. Platelets. Academic Press, Boston. pp. 291-296.
10. Nazarian, R.M. and M. Laposata. Anticoagulant Therapies, 2007. In McKean, S., Halasyamani, L., Bennett A.L., eds. Hospital Medicine: Just the Facts. McGraw-Hill, USA, New York.
11. Laposata, M. and C. Soupir. 2008. In Kleinman, R.E. ed. Conversion of SI Units. Pediatric Nutrition Handbook. Am. Acad. of Pediatr.
12. Laposata, M. Laboratory Medicine. Publisher – Decision Support in Medicine (Electronic Program). Chapters: “Antiphospholipid Antibody Syndrome ,” “Antiplasmin Deficiency,” “Factor V Deficiency – Acquired,” “Factor VIII Inhibitors in Patients With Congenital Factor VIII Deficiency,” “Factor VIII Inhibitors in Patients Without Congenital Factor VIII Deficiency,” “Hemophilia A (Factor VIII Deficiency) – Congenital,” “Hemophilia B (Factor IX Deficiency) – Acquired,” “Hemophilia B (Factor IX Deficiency) – Congenital,” “Platelet Function Disorder Produced by Glycoprotein IIb/IIIa Inhibitors,” “Von Willebrand Disease – Congenital,” “Von Willebrand Disease – Acquired.” in Clinical Decision Support: Laboratory Medicine. Edited by Laposata M, Alter D, Melanson SEF. 2013. Decision Support in Medicine, LLC, Wilmington, DE.
13. Laposata, M. Concepts in Laboratory Medicine, 2019. In Laposata M, ed. Laposata’s Laboratory Medicine: The Diagnosis of Disease in the Clinical Laboratory. Third Edition. (Lange Series textbook). McGraw-Hill. China. pp. 1-17.
14. Laposata, M., J. H. Nichols, P. Steele, T. P. Stricker, and M.K. Sarkar. Methods, 2019. In Laposata M, ed. Laposata’s Laboratory Medicine: The Diagnosis of Disease in the Clinical Laboratory. Third Edition. (Lange Series textbook). McGraw-Hill. China. pp. 19-71.
15. Nichols J.H, N. J. Rutherford, and M. Laposata. Toxicology, 2019. In Laposata M, ed. Laposata’s Laboratory Medicine: The Diagnosis of Disease in the Clinical Laboratory. Third Edition. (Lange Series textbook). McGraw-Hill. China. pp. 177-203.
16. Laposata, M. Blood Vessels, 2019. In Laposata M, ed. Laposata’s Laboratory Medicine: The Diagnosis of Disease in the Clinical Laboratory. Third Edition. (Lange Series textbook). McGraw-Hill. China. pp. 217-203.
17. Van Cott, E.M., and M. Laposata. Bleeding and Thrombotic Disorders, 2019. In Laposata M, ed. Laposata’s Laboratory Medicine: The Diagnosis of Disease in the Clinical Laboratory. Third Edition. (Lange Series textbook). McGraw-Hill. China. pp. 281-319.
18. Laposata, M. The Gastrointestinal Tract, 2019. In Laposata M, ed. Laposata’s Laboratory Medicine: The Diagnosis of Disease in the Clinical Laboratory. Third Edition. (Lange Series textbook). McGraw-Hill. China. pp. 389-397.
19. Alter, D.N., and M. Laposata. Pancreatic Disorders, 2019. In Laposata M, ed. Laposata’s Laboratory Medicine: The Diagnosis of Disease in the Clinical Laboratory. Third Edition. (Lange Series textbook). McGraw-Hill. China. pp. 417-429.
20. Woodworth, A., V. Lakhani, and M. Laposata. The Endocrine System, 2019. In Laposata M, ed. Laposata’s Laboratory Medicine: The Diagnosis of Disease in the Clinical Laboratory. Third Edition. (Lange Series textbook). McGraw-Hill. China. pp. 481-532.

1. Jordan, C.D., J.G. Flood, M. Laposata, and K.B. Lewandrowski. 1992. Normal reference laboratory values. N. Engl. J. Med. 327:718-724.
2. Handin, R.H. and M. Laposata. 1993. A 72-year-old woman with a coagulopathy and bilateral thigh masses. N. Engl. J. Med. 328:121-128.
3. Cines, D.B. and M. Laposata. 1995. A 70-year old woman with recent breast cancer, atrial fibrillation, and the rapid onset of petechiae and neurologic deterioration. N. Engl. J. Med. 332:1363-1370.
4. Rennke, H.G. and M. Laposata. 1999. A 54-year old woman with acute renal failure and thrombocytopenia. N. Engl. J. Med. 340:1900-1908.
5. Laposata, M., E.M. Van Cott, and M. Lev. 2007. A woman with epistaxis, hematemesis, and altered mental status. N. Engl. J. Med. 356:174-182.
6. Dzik, W.H., M. Laposata, M. Hertl, W.S. Sandberg, M. Chatterji, and J. Misdraji. 2008.
7. Case records of the Massachusetts General Hospital. Case 38-2008. A 58-year-old man with hemophilia A, hepatocellular carcinoma, and intractable bleeding. N. Engl. J. Med. 359:2587-2597.

1. Laposata, M. and J. Teruya. 1990. Reappraisal of preoperative coagulation testing. Am. J. Clin. Pathol. 94:795-796.
2. Laposata, M. 1999. The prothrombin G20210A mutation: A new high-prevalence congenital risk factor for thrombosis. Gastroenterology. 116:213-215.
3. Laposata, M. 2001. Point-of-care testing in coagulation: Stepping gently forward. Clin. Chem. 47:801-802.
4. Laposata, M. 2004. Patient Specific Narrative Interpretations of Complex Clinical Laboratory Evaluations: Who is Competent to Provide Them? Clin. Chem. 50:471-472.
5. Plebani, M. and M. Laposata. 2006. Translational research involving new biomarkers of disease: A leading role for the pathologist. Am. J. Clin. Path. 126:1-3.
6. Laposata, M., M.A. Proytcheva, J.C. Rutledge, and C.W. Stratton. 2010. Professional Quality Assurance in Laboratory Medicine: What about the Competency of Laboratory Directors? Am. J. Clin. Path. 134:706-708.
7. Marques, M.B., J. Anastasi, E. Ashwood, B. Baron, R. Fitzgerald, M. Fung, M. Krasowski, M. Laposata, T. Nester, and H. Rinder. 2010. The Clinical Pathologist as Consultant. Am. J. Clin. Path. 135:11-12.
8. Laposata, M. 2012. Teaching Laboratory Management to Pathology Residents: What Skill Set Are We Trying to Impart? Am. J. Clin. Path. 137:16-18.
9. Laposata, M. 2014. Errors in Clinical Laboratory Test Selection and Result Interpretation: Commonly Unrecognized Mistakes as a Cause of Poor Patient Outcome.Diagnosis 1:85-87.
10. Laposata, M., M.B. Cohen. 2016. It’s our turn: Implications from the Institute of Medicine’s Report on Diagnostic Error. Arch. Pathol. Lab. Med. 140:505-507.
11. Laposata, M. 2016. Insufficient teaching of laboratory medicine in US medical schools. Acad. Pathol. 3:1-2.
12. Laposata, M. A new kind of autopsy for 21st century medicine. 2017. Arch. Pathol. Lab. Med. 141:887-888.
13. Laposata, M. Why have doctors stopped asking for autopsies? Will a different type of autopsy change this? 2017. Autops. Case Rep. 7:1-2.
14. Plebani, M, M. Laposata, and G. Lippi. 2019. A manifesto for the future of laboratory medicine professions. Clin. Chem. Acta. 489:49-52.

1. Laposata, M. 1988. Academic promotion at a Medical School (letter). N. Engl. J. Med. 319, 799.
2. Conjoint Task Force on Clinical Pathology Residency Training (M. Laposata one of ten contributors). 1995. Gralyn Conference Report: Recommendations for reform of clinical pathology residency training. Am. J. Clin. Path. 103:127-129.
3. Lewandrowski, K.B. and M. Laposata. 1995. Correspondence: Bedside Capillary Glucose Testing. Am. J. Med. 99:576-577.
4. Van Cott, E.M. and M. Laposata. 2001. Cysteine and venous thrombosis: A case report. Am. J. Clin. Path. 117:165.
5. Laposata, M., B.P. O’Sullivan, S.D. Freedman. 2004. Eicosanoids in Cystic Fibrosis. N. Engl. J. Med. 350:2000-2001.
6. Piva, E., L. Sciacovelli, M. Zaninotto, M. Plebani, M. Laposata. 2012. Critical Laboratory Results: Communication is Just One of the Problems. Am. J. Clin. Path. 137:164.

1. Dzieczkowski, J., K.B. Lewandrowski, and M. Laposata. 1991. The laboratory diagnosis of pheochromocytoma. Am. Soc. Clin. Pathol. Clinical Chemistry Check Sample Vol. 31, No. 4.
2. Laposata, M. 1992. Algorithms for Diagnosis of Disorders in Hemostasis. Booklet printed by Coulter/Instrumentation Laboratories.
3. Teruya, J. and M. Laposata. 1993. Lipids: Biochemistry to clinical significance. Am. Soc. Clin. Pathol. Clinical Chemistry Check Sample. Vol. 33, No. 6.
4. Laposata, M. 1997. Fatty acid ethyl esters: Ethanol metabolites with a role in ethanol-induced organ damage and monitoring ethanol intake. Newsletter for the International Society for the Study of Fatty Acids and Lipids (ISSFAL). 4:9-15.
5. Laposata, M. 1997. Fatty acid ethyl ester: A new marker for ethanol intake. Lab Medica International. 14:12-14.
6. Laposata, M. 1997. Fatty acids: The dangerous and not-so-dangerous. Med. Lab. Observer. 29:40-49.
7. Laposata, M. and D.H. MacMillan. 1998. Reflex testing and its significance in the world of managed care. Lab. Med. 29:595-596.
8. Laposata, M. 1998. Providing more than just a test result: The value-added services from the MGH clinical laboratory. Newsletter of the Arizona Society of Pathologists. IX, 1-9.
9. Laposata, M. 1998. Fatty acid ethyl esters: Non- oxidative metabolites of ethanol. Addiction Biol 3:5-14.
10. Laposata, M. and E.M. Van Cott. 2000. How to work up hypercoagulability. CAP Today; 15:24-26.
11. Laposata, M. 2001. Providing Value Added Services. Advance, 9:14-15.
12. MacMillan, D.H. and M. Laposata. 2001. Consultation in clinical pathology and the Internet: A new service. Advance, 10:18-20.
13. Soderberg, B.L. and M. Laposata. 2001. Fatty acid ethyl esters: Markers of ethanol intake. American Clinical Laboratory, September, pp.18-20.
14. Laposata, M. and E.M. Van Cott. 2002. Current approaches to the work-up of hypercoagulability. News path. A publication of the College of American Pathologists. Winter.
15. MacMillan, D.H. and M. Laposata. 2002. Income Opportunities for Lab Medicine. Advance, 11:35-37.
16. Van Cott, E.M. and M. Laposata. 2003. Algorithms for hypercoagulability testing. Lab. Med. 34:216-222.
17. Refaai, M., and M. Laposata. 2003. A primer on bleeding and thrombotic disorders. Advance. April: 46-55.
18. Dighe, A.S. and M. Laposata. 2004. Making Laboratory More Valuable to Physicians and Patients. Bulletin of the Royal College of Pathologists. 127: July: 11-14.
19. Dighe, A.S. and Laposata, M.L. 2004. Making the laboratory a partner in patient safety. Clinical Leadership & Management Review, 18:356-60.
20. Laposata, M. 2014. How can a diagnostic management team improve patient care and save money? Long-standing and rapidly worsening problem of obtaining an accurate diagnosis quickly. NACB – Scientific Shorts (formerly NACB Blog).
21. Laposata M. 2017. Curing our diagnostic disorder: The disease has a variety of symptoms: Medical errors, poor utilization management, professional misunderstandings. Could the diagnostic management team prove to be a panacea? The Pathologist (feature article).

1. Laposata, M. and Rohde, R.E. 2018. Preventing diagnostic errors by uniting the clinical laboratory with direct patient care. https://www.elsevier.com/connect/preventing-diagnostic-errors-by-uniting-the-clinical-laboratory-with-direct-patient-care